August 2013, Vol 6 ADA 2013 Highlights
Chicago, IL—At the 2013 American Diabetes Association (ADA) annual meeting, John E. Anderson, MD, President of Medicine & Science of the ADA, hosted the President’s Oral Research Sessions I and II, one session focused on basic science and the other on clinical and behavioral science. A subcommittee for the ADA’s Program Committee selected the abstracts of the 2 sessions. Commenting on these sessions, Dr Anderson said, “The Presidential Oral Research Sessions highlight the best and most promising research of all the abstracts submitted to the Scientific Sessions Planning Committee this year.”
Chicago, IL—An intensive lifestyle intervention designed for weight loss had no significant effect on the risk of cardiovascular (CV) events after a decade compared with diabetes support and education, but it did lead to reduced use of antidiabetes and cardiac medications, fewer hospitalizations, and lower cost, reported researchers at the 2013 American Diabetes Association annual meeting.
Chicago, IL—The new drug class of sodium glucose cotransporter (SGLT)-2 inhibitors was the subject of several poster presentations at the 2013 American Diabetes Association annual meeting. In addition to lowering blood glucose levels in a series of phase 3 clinical trials, these agents show weight-loss benefits as well.
Chicago, IL—Diabetes is known to confer approximately a 2-fold increased risk for vascular disease, independent of other cardiovascular (CV) risk factors. The topic was discussed in a session at the 2013 American Diabetes Association (ADA) annual meeting. The presence of diabetes is equivalent in risk to a history of coronary heart disease.
Chicago, IL—Hypoglycemia is a serious concern in elderly patients with type 2 diabetes who often require insulin therapy. Two new analyses presented as late-breaking posters at the 2013 American Diabetes Association annual meeting showed that adding linagliptin to basal insulin in elderly patients reduces the incidence of hypoglycemia in diabetic patients.
Reductions in HbA1c Levels, Hypoglycemia, and Weight with Linagliptin in Patients with Type 2 Diabetes and Renal Impairment
Chicago, IL—It is estimated that approximately 66% of patients with type 2 diabetes are at risk for declining renal function. A new double-blind, randomized trial of patients with type 2 diabetes and moderate-to-severe renal impairment—estimated glomerular filtration rate (eGFR) <60 mL/min/1.73 m2—showed that the dipeptidyl peptidase (DPP)-4 inhibitor linagliptin (Tradjenta) significantly reduced hemoglobin (Hb) A1c compared with placebo at 12 weeks (the primary end point); compared with glimepiride in the 40-week extension study, there was less hypoglycemia with linagliptin.
Chicago, IL—The final results of the Look AHEAD study showed that an intensive lifestyle intervention program provides a range of benefits in patients with type 2 diabetes who were overweight and obese. However, it had no impact on the primary outcome of reducing cardiovascular (CV) morbidity and mortality.
Page 2 of 2
Results 11 - 19 of 19
Results 11 - 19 of 19